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Bipolar disorder (BD) is a highly heritable psychiatric disorder characterised by recurrent episodes of
mania and depression. Many studies have reported altered gene expression in BD, some of which may be
attributable to the dysregulated expression of miRNAs. Studies carried out to date have largely studied
medicated patients, so it is possible that observed changes in miRNA expression might be a consequence
of clinical illness or of its treatment. We sought to establish whether altered miRNA expression might
play a causative role in the development of BD by studying young, unmedicated relatives of individuals
with BD, who are at a higher genetic risk of developing BD themselves (high-risk individuals). The
expression of 20 miRNAs previously implicated in either BD or schizophrenia was measured by qRT-PCR
in whole-blood samples from 34 high-risk and 46 control individuals. Three miRNAs, miR-15b, miR-132
and miR-652 were up-regulated in the high-risk individuals, consistent with previous reports of
increased expression of these miRNAs in patients with schizophrenia. Our ﬁndings suggest that the
altered expression of these miRNAs might represent a mechanism of genetic susceptibility for BD.
Moreover, our observation of altered miRNA expression in the blood prior to the onset of illness provides
hope that one day blood-based tests may aid in the risk-stratiﬁcation and treatment of BD.
© 2015 Published by Elsevier Ltd.1. Introduction
Bipolar disorder (BD) is a severe psychiatric disorder charac-
terised by recurrent episodes of mania and depression, which
occurs with a lifetime prevalence of approximately 0.6%n, Centre for Genomic and
olecular Medicine, The Uni-
e Road, Edinburgh EH4 2XU,
.M. Walker), joanna.rybka1@
(S.M. Anderson), Helen.
ms.ed.ac.uk (R. Boxall), Jess.
avid.porteous@igmm.ed.ac.uk
Intosh), Kathy.Evans@igmm.
cs, CollegiumMedicum UMK,(Merikangas et al., 2011). The heritability of BD is estimated to be
around 0.85 (McGufﬁn et al., 2003) and ﬁrst-degree relatives of
individuals with BD have a seven-fold risk of developing BD
compared to the general population (Lichtenstein et al., 2009),
indicating a substantial genetic component to the aetiology of
this disorder. In addition to being at an elevated risk of devel-
oping BD, the ﬁrst-degree relatives of BD patients are also at an
increased risk of developing schizophrenia and major depressive
disorder (MDD) (Lichtenstein et al., 2009; Rasic et al., 2014),
indicating a shared component to the aetiology of these psy-
chiatric disorders.
Altered gene expression has been identiﬁed in multiple studies
of the blood and post-mortem brains of individuals with psychiatric
disorders (Kumarasinghe et al., 2012; Seifuddin et al., 2013). Gene
ontology analysis of these genes has implicated biological processes
with apparent relevance to the pathogenesis of psychiatric illness
such as synaptic function. More recently, altered microRNA
Table 1
Demographic characteristics of the sample.
Control High-risk Test statistic p-value
Age (SD) 26.2 (4.24) 24.9 (4.98) 1.23 0.224
Gender
Female (%) 26 (56.5) 18 (52.9) NA 0.707
Male (%) 20 (43.5) 16 (47.1)
RIN (SD) 7.05 (0.915) 7.09 (0.859) 0.211 0.833
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mechanism for both BD and schizophrenia (Mafﬁoletti et al., 2014).
Multiple miRNAs have been found to show dysregulated expression
in individuals with these conditions both in the brain (Banigan
et al., 2013; Beveridge et al., 2010; Miller et al., 2012; Moreau
et al., 2011; Perkins et al., 2007; Santarelli et al., 2011; Smalheiser
et al., 2014) and in the periphery (Gardiner et al., 2012; Lai et al.,
2011). Consistent with these changes, increased expression of
components of the miRNA processing pathway has been detected
in the brains of schizophrenic patients (Beveridge et al., 2010;
Santarelli et al., 2011). Additionally, the expression of Ago2, which
is involved in effecting miRNA-induced silencing (Cenik and
Zamore, 2011), as well as the regulation of mature miRNA expres-
sion and miRNA processing (Diederichs and Haber, 2007), has been
found to be down-regulated in peripheral blood mononuclear cells
in schizophrenic patients (Gardiner et al., 2013). miRNAs are short
(~22 nt) RNA sequences that can each target hundreds of mRNAs by
complementarity to the 30 untranslated region, generally resulting
in the suppression of gene expression either by affecting mRNA
stability or translation (Valencia-Sanchez et al., 2006). As such,
changes in miRNA expression might underlie some of the observed
changes in mRNA and protein expression observed in BD and
schizophrenia.
Studies reporting altered miRNA expression in BD and
schizophrenia have almost exclusively been carried out on in-
dividuals who have been ill for several years and are taking
medication. It is, therefore, often not possible to determine
whether observed changes in miRNA expression are a primary
causative event, occur as a consequence of illness progression, or
are induced by medication. Studies in primary neuronal cultures,
cell lines and animal models have demonstrated that several
miRNAs show altered expression following treatment with mood-
stabilisers and/or antipsychotics (Chen et al., 2009; Gardiner et al.,
2014; Hunsberger et al., 2013; Santarelli et al., 2013; Zhou et al.,
2009), further supporting the need to study unmedicated
individuals.
To our knowledge, only one study has measured miRNA
expression in unmedicated individuals diagnosed with BD. Rong
et al. (2011) measured a single miRNA, miR-134, and demon-
strated reduced plasma expression in drug-free manic patients
with BD1, which increased in response to treatment with mood-
stabilisers.
We sought to further understanding of the involvement of
altered miRNA expression in the aetiology of BD by measuring
miRNA expression in young, unaffected relatives of patients
with BD who are at higher genetic risk of developing BD
(henceforth referred to as high-risk individuals). The high-risk
and control individuals were selected from a larger cohort
recruited as part of the Edinburgh-based Bipolar Family Study
(BFS). Individuals from this cohort have undergone structural
and functional magnetic resonance imaging, which has revealed
reduced white matter integrity and alterations in the activity of
the amygdala and insula, brain structures previously implicated
in the pathophysiology of psychiatric illness, in high-risk in-
dividuals (Sprooten et al., 2011; Whalley et al., 2011, 2013b).
Additionally, high-risk individuals have been shown to carry
more BD-associated variants than control subjects, as indicated
by a signiﬁcantly higher BD polygene score (Whalley et al.,
2013a).
Here, we measured the expression of 20 miRNAs previously
implicated in the pathogenesis of BD and/or schizophrenia in
whole-blood samples from high-risk and control individuals. As
such, we aimed to identify miRNAs whose expression is altered
prior to illness onset and which, thus, may play a causative role in
illness development.2. Methods
2.1. Participants
We examined 34 unaffected individuals at higher genetic risk of
developing a mood disorder and 46 control subjects. These in-
dividuals were recruited as part of The Bipolar Family Study (BFS),
as described previously (Sprooten et al., 2011; Whalley et al., 2011).
High-risk subjects met the following selection criteria: (i) at least
one ﬁrst-degree or two second-degree relatives suffering from
BD1; (ii) no personal history of BD; and (iii) aged 16e25 at the time
of recruitment. Control individuals of a similar agewere selected on
the basis that they did not have a personal history of BD or a family
history of any mood disorder amongst their ﬁrst-degree relatives.
Exclusion criteria for both groups were: a history of major
depression, mania, or hypomania, psychosis, generalized anxiety
disorder, panic disorder, eating disorder, substance dependence, an
IQ < 70 or clinical diagnosis of learning disability, any major
neurological disorder or history of head injury that included loss of
consciousness, and any contraindications to magnetic resonance
imaging (MRI). Only unrelated individuals were included. All par-
ticipants provided written informed consent and the study was
approved by the Multicentre Research Ethics Committee for
Scotland.
2.2. Selection of miRNAs for assessment
MicroRNAs were selected for assessment on the basis that they
were either implicated in the pathogenesis of BD or schizophrenia
through: (i) altered expression in patients or (ii) altered expression
in response to treatment with a mood-stabilising drug. A literature
search was carried out using PubMed using the terms “micro RNA”,
“bipolar disorder”, “schizophrenia”, “lithium”, and “valproate”,
together with commonly used abbreviations, in August 2011.
2.3. Extraction of blood RNA
Blood for RNA extraction (3 ml) was collected in Tempus Blood
RNA Tubes (Life Technologies). RNA was extracted using MagMAX
for Stabilized Blood Tubes RNA Isolation Kit (Life Technologies),
according to the manufacturer's instructions. RNA yield and quality
were assessed using the Agilent Bioanalyzer.
2.4. Assessment of miRNA expression
Assessment of miRNA expression was carried out using TaqMan
MicroRNA Assays (Life Technologies; SOM Table 1), following the
manufacturer's protocol for custom reverse transcription and pre-
ampliﬁcation pools (https://tools.lifetechnologies.com/content/sfs/
manuals/cms_094060.pdf). Brieﬂy, for all genes of interest and
reference genes, a custom reverse transcription (RT) pool was
created by combining 10 ul of each 5 RT primer and a custom pre-
ampliﬁcation pool was created by combining 10 ul of each 20
TaqMan MicroRNA Assay. The RT reaction was performed using
100 ng RNA. A half volume reaction without the RT enzyme was
also performed using 50 ng RNA (RT negative). cDNA was pre-
Table 2
Comparison of miRNA expression levels in whole-blood samples from high-risk and control individuals. Nominally signiﬁcant (p  0.05) p-values are indicated in bold.
microRNA Median expression (IQR) ManneWhitney
U statistic
p-value
(uncorrected)
p-value (Bonferroni-corrected) Fold-change
High-risk Control
let-7b 0.953 (0.696e1.35) 0.919 (0.631e1.29) 523 0.605 1.00 1.04
let-7c 0.834 (0.644e1.13) 0.877 (0.583e1.18) 555 0.965 1.00 1.05
miR-15b 1.07 (0.744e1.42) 0.825 (0.440e0.951) 373 0.0166 0.266 1.29
miR-34a 0.637 (0.346e0.942) 0.630 (0.348e0.856) 468 0.737 1.00 1.01
miR-132 1.04 (0.830e1.17) 0.777 (0.651e1.08) 385 0.0249 0.398 1.34
miR-133b 0.682 (0.307e1.21) 0.612 (0.231e1.13) 444 0.504 1.00 1.12
miR-134 0.657 (0.397e0.876) 0.576 (0.263e0.970) 489 0.808 1.00 1.14
miR-145 0.777 (0.399e1.16) 0.623 (0.421e0.962) 495 0.485 1.00 1.25
miR-195 0.828 (0.639e1.18) 0.738 (0.589e1.09) 476 0.272 1.00 1.12
miR-212 0.861 (0.780e1.37) 0.946 (0.640e1.31) 500 0.778 1.00 1.10
miR-221 0.820 (0.673e1.08) 0.734 (0.566e0.906) 430 0.0943 1.00 1.12
miR-432 0.832 (0.549e1.26) 0.826 (0.438e1.30) 538 0.739 1.00 1.01
miR-449 0.734 (0.439e1.13) 0.806 (0.534e1.40) 566 0.317 1.00 1.10
miR-548d-5p 1.21 (0.783e2.17) 1.33 (0.701e1.90) 484 0.907 1.00 1.10
miR-572 1.05 (0.791e1.20) 0.876 (0.716e1.06) 442 0.226 1.00 1.20
miR-652 0.898 (0.725e1.21) 0.712 (0.567e1.02) 361 0.01076 0.172 1.26
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merase chain reaction (qRT-PCR). qRT-PCR reactions were per-
formed using an ABI Prism 7900 Sequence Detection System
(Applied Biosystems). Expression levels were calculated using the
relative standard curve method and miRNA-of-interest expression
levels were normalised to the geometric mean of the expression
levels of four small reference RNAs (RNU6B, RNU47, SNORD68, and
SNORD95). These reference RNAs were selected from an initial pool
of seven (RNU6B, RNU47, SNORD96A, SNORD61, SNORD68,
SNORD95, and SNORD72) on the basis of geNorm analysis
(Vandesompele et al., 2002). Each sample was measured in tech-
nical triplicate and the mean of this triplicate used in downstream
analyses. Outlier samples, deﬁned as data points falling outside of
the range deﬁned by median ± 3 inter-quartile range, were
excluded.
2.5. Statistical analysis
Differences in age and RIN between the control and high-risk
groups were assessed using two-tailed unpaired Student's t-tests.Table 3
Summary of the top ﬁndings from Ingenuity Pathway Analysis of the mRNA targets of m
Name p-value
Canonical pathways
Glioblastoma multiforme signalling 9.03  108
PTEN signalling 1.51  107
STAT3 signalling 1.75  107
TGF-b signalling 3.78  107
PI3K/Akt signalling 4.13  107
Name p-value range
Molecular and cellular functions
Cell cycle 5.36  1017e4.34  10
Cellular assembly and organization 1.16  1015e4.29  10
Cellular function and maintenance 1.16  1015e4.34  10
Cell death and survival 1.29  1015e3.91  10
Cellular growth and proliferation 1.02  1014e4.27  10
Physiological system development and function
Organismal survival 9.87  1015e1.73  10
Tissue development 2.15  1013e4.27  10
Embryonic development 6.22  1012e4.12  10
Organismal development 6.22  1012e4.29  10
Nervous system development and function 5.50  1011e4.34  10
Diseases and disorders
Cancer 1.26  1026e4.00  10
Organismal injury and abnormalities 2.95  1016e4.41  10
Reproductive system disease 2.95  1016e3.91  10
Gastrointestinal disease 4.28  1012e1.00  10
Developmental disorder 2.41  108e3.91  10The between-group difference in gender was assessed using Fisher's
exact test. In all cases a p-value of 0.05 was considered statistically
signiﬁcant.
Differences in gene expression between the control and high-
risk subjects were assessed using two-tailed ManneWhitney U
tests. A p-value of 0.05 was considered to be nominally statisti-
cally signiﬁcant. A Bonferroni correction was implemented to cor-
rect for multiple testing. The pairwise correlation between miRNA
expression levels was assessed by Spearman's rank correlation
coefﬁcient.2.6. Identiﬁcation and functional analysis of miRNA targets
The regulatory targets of differentially expressed miRNAs were
identiﬁed using Ingenuity Pathway Analysis's (IPA) miRNA Target
Filter function, which queries TarBase and miRecords for experi-
mentally validated miRNA targets and TargetScan for predicted
miRNA targets. In addition, the Ingenuity Knowledge Base contains
information on miRNA targets from the peer-reviewed literature.iR-15b.
q-value Ratio
2.76  105 36/146 (0.247)
2.76  105 31/118 (0.263)
2.76  105 23/73 (0.315)
3.90  105 25/87 (0.287)
3.90  105 31/123 (0.252)
q-value range No. molecules
4 1.13  1013e1.50  102 278
4 2.20  1012e1.50  102 385
4 2.20  1012e1.50  102 477
4 2.20  1012e1.41  102 613
4 1.17  1011e1.49  102 621
8 1.17  1011e3.29  106 425
4 1.75  1010e1.49  102 596
4 3.04  109e1.46  102 487
4 3.04  109e1.40  102 598
4 1.92  108e1.50  102 349
4 2.43  1022e1.42  102 1522
4 6.32  1013e1.51  102 886
4 6.32  1013e1.41  102 735
4 2.22  109e5.29  103 708
4 4.38  106e1.41  102 297
Fig. 2. Spearman's rank correlation coefﬁcients for the three nominally differentially
expressed miRNAs, miR-15b, miR-132 and miR-652.
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gets was submitted to IPA core analysis to identify canonical
pathways (deﬁned as manually curated, well-characterised meta-
bolic and cell signalling pathways), diseases and biological func-
tions that were enriched amongst the inputted list. IPA assesses
enrichment using the right-tailed Fisher's exact test. As multiple
hypotheses were tested, the BenjaminieHochberg false discovery
rate (FDR) method was implemented to calculate q-values. We
deﬁned statistical signiﬁcance as q  0.05. The Ingenuity Knowl-
edge Base was used as the reference set and the following param-
eter settings were used: experimentally observed direct and
indirect relationships identiﬁed in all species.3. Results
3.1. Sample demographics
Between-group differences in age, gender and RNA integrity, as
represented by the RNA Integrity Number (RIN), were assessed as
these factors can alter gene expression. No signiﬁcant differences
were observed (all p > 0.05; Table 1; SOM Table 2).3.2. Selection of miRNAs for assessment
Twenty miRNAs were selected for assessment on the basis that
they had previously been implicated in the pathogenesis of BD or
the closely related condition, schizophrenia (SOM Table 3). Of
these, 16 miRNAs (miR-134, miR-212, miR-133b, miR-449, miR-34a,
miR548d-5p, let-7b, let-7c, miR-15b, miR-132, miR-145, miR-195,
miR-221, miR-432, miR-572, and miR-652) were successfully
detected in our whole-blood cDNA samples. miR-15a, miR-154*,
miR-548d-3p, and miR-564 were not reliably detected in a sufﬁ-
cient number of samples to permit analysis.3.3. Identiﬁcation of differentially expressed miRNAs
Of the sixteen reliably detected miRNAs, three, miR-15b, miR-
132, and miR-652, showed a nominally signiﬁcant increase in
expression in the high-risk subjects compared to the control sub-
jects (miR-15b: p ¼ 0.0166, fold-change (FC) ¼ 1.29; miR-132:
p ¼ 0.0249, FC ¼ 1.34; miR-652: p ¼ 0.0108, FC ¼ 1.26; Fig. 1;
Table 2). None of these changes remained signiﬁcant after imple-
menting a Bonferroni correction for multiple testing (all p  0.172).
The expression levels of all three dysregulated miRNAs were,
however, positively correlated (Fig. 2).Fig. 1. Beeswarm plots showing normalised expression values for miR-15b (A), miR-132 (B)
median expression value. The p-value in the bottom right-hand corner of each plot represe3.4. Pathway analysis of the targets of differentially expressed
miRNAs
To identify biological pathways that might be affected by the
differential expression of miR-15b, miR-132, and miR-652 we car-
ried out pathway analysis. IPA's miRNA Target Filter function was
used to generate lists of experimentally observed and predicted
targets of the three dysregulated miRNAs. miR-15b was found to
have 2020 targets (187 experimentally observed, 1833 predicted),
miR-132 was found to have 767 targets (9 experimentally observed,
758 predicted), miR-652 was found to have 205 targets (all pre-
dicted). The results of these analyses are summarised in Tables 3e5.
Consistent with their proposed role in psychiatric illness, the
targets of both miR-15b and miR-132 were enriched for molecules
involved in Nervous System Development and Function (miR-15b:
q ¼ 1.92  108e1.50  102; miR-132:
q ¼ 4.98  108e2.83  103). For both miRNAs, PI3K/Akt Signal-
ling (miR-15b: q ¼ 4.13  107; miR-132: q ¼ 1.17  105) was
amongst the top canonical pathways and the related PTEN Signal-
ling pathway was amongst miR-15b's top canonical pathways
(q¼ 1.51107). The targets of miR-132 were found to be enriched
for molecules in the IPA category Neurological Diseases
(q ¼ 1.23  107e2.71  103). Within this category, the most
signiﬁcant sub-classiﬁcation was Cognitive Impairment
(q¼ 3.03105), followed byMental Retardation (q¼ 1.38 104).
The Neurological Diseases sub-classiﬁcation Schizophrenia was
also enriched for miR-132's target mRNAs (q ¼ 1.65  102).
Additionally, Axonal Guidance Signalling was a top canonical
pathway for the targets of miR-132 (q ¼ 7.03  107).
Pathway analysis of miR-652's targets did not yield any results
that survived multiple testing correction. Canonical pathways
attaining nominally signiﬁcant p-values included Reelin Signalling
in Neurons (p ¼ 8.88  104) and GABA Receptor Signalling
(p ¼ 3.64  103). Amongst the diseases showing nominally sig-
niﬁcant enrichment for the targets of miR-652 was the category of
Neurological Diseases (p ¼ 2.61  104e4.61  102). Within this
category, the sub-classiﬁcations of Schizoaffective Disorder
(p ¼ 1.84  103) and Bipolar Disorder (p ¼ 7.10  103) were
signiﬁcantly enriched., and miR-652 (C) in high-risk and control individuals. The horizontal bar indicates the
nts the signiﬁcance (uncorrected) of the ManneWhitney U test.
Table 4
Summary of the top ﬁndings from Ingenuity Pathway Analysis of the mRNA targets of miR-132.
Name p-value q-value Ratio
Canonical pathways
Molecular mechanisms of cancer 8.57  108 3.36  105 36/365 (0.099)
Axonal guidance signalling 7.03  107 1.38  104 38/432 (0.088)
PI3K/AKT signalling 1.17  105 1.53  103 16/123 (0.13)
Melanocyte development and pigmentation signalling 5.65  105 5.54  103 12/84 (0.143)
B cell receptor signalling 9.12  105 7.01  103 18/176 (0.102)
Name p-value range q-value range No. molecules
Molecular and cellular functions
Gene expression 7.67  1013e1.99  103 2.48  109e4.48  102 180
Cellular growth and proliferation 9.47  1011e2.81  103 1.02  107e5.49  102 257
Cellular development 2.10  1010e2.83  103 1.70  107e5.49  102 251
Cell death and survival 7.76  109e2.72  103 1.18  106e5.37  102 231
Cell cycle 4.16  108e2.75  103 1.30  105e5.41  102 114
Physiological system development and function
Organismal survival 3.37  1013e2.68  107 2.48  109e6.35  105 190
Embryonic development 2.46  109e2.83  103 1.14  106e5.49  102 190
Organismal development 2.46  109e2.72  103 1.14  106e5.37  102 230
Tissue morphology 8.31  109e2.83  103 3.13  106e5.49  102 158
Nervous system development and function 4.98  108e2.83  103 1.42  105e5.49  102 172
Diseases and disorders
Cancer 6.91  1011e2.80  103 9.03  108e5.49  102 574
Gastrointestinal disease 6.91  1011e2.61  103 9.03  108e5.25  102 305
Developmental disorder 7.24  108e2.33  103 1.95  105e4.95  102 155
Neurological disease 1.23  107e2.71  103 3.03  105e5.37  102 172
Organismal injury and abnormalities 1.27  106e2.83  103 2.30  104e5.49  102 282
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In recent years, it has become clear that changes in miRNA
expression are likely to play a role in the pathogenesis of psychiatric
disorders, and have the potential to act as peripheral biomarkers of
disease and markers of therapeutic response (Fan et al., 2014; Lai
et al., 2011; Mafﬁoletti et al., 2014; Rong et al., 2011). Most
studies carried out to date have focussed on the role of miRNAs in
schizophrenia; however, studies in patients with BD have also
found evidence for altered function (Kim et al., 2010; Moreau et al.,
2011; Rong et al., 2011; Smalheiser et al., 2014). These studies have,
however, almost exclusively studied medicated individuals who
have been ill for some time, leaving open the possibility that
observed changes in miRNA expression are a consequence of illness
progression or treatment.
The need to establish whether altered miRNA expression plays a
causal role in the development of BD prompted us to study a group
of individuals who, due to family history, are at a higher genetic risk
of developing BD than the general population. The expression of 20
miRNAs, selected for a priori evidence of involvement in BD or
schizophrenia, was measured in these high-risk individuals and
compared with a control group. Three miRNAs, miR-15b, miR-132
and miR-652, which have previously been implicated in schizo-
phrenia, show nominally signiﬁcant increases in expression.
Although our ﬁndings do not remain signiﬁcant after implementing
the Bonferroni correction, it is important to note that the highly
correlated expression of the miRNAs assessed here will render this
correction overly conservative. The resultant inﬂation in type 2
error rate is likely to be further compounded by the fact that each
miRNAwas selected based on a priori evidence for the involvement
of its altered expression in bipolar disorder and/or schizophrenia.
Although replication is essential, our ﬁndings provide suggestive
evidence that the dysregulated expression of these miRNAs might
represent a mechanism underlying genetic susceptibility for BD.
In keeping with ﬁndings in patients with schizophrenia, the
expression of all three miRNAs was increased in the high-risk
subjects. miR-15b was previously found to show increased
expression in the superior temporal gyrus (STG) and dorsolateralprefrontal cortex (DLPFC) of patients with schizophrenia (Beveridge
et al., 2010). miR-132 has been found to show altered expression in
schizophrenia patients in two studies; however, they disagree with
regard to the direction of change in miR-132's expression (Kim
et al., 2010; Miller et al., 2012). Both studies measured miR-132
expression in the prefrontal cortex (PFC); however, Kim et al.
(2010) observed increased expression in schizophrenia while
Miller et al. (2012) observed decreased expression in two inde-
pendent cohorts of patients with schizophrenia. An increase in the
expression of miR-652 expression has been observed in the DLPFC
of patients with schizophrenia (Santarelli et al., 2011). Interestingly,
miR-652 was one of seven miRNAs found to form a blood-based
expression signature that was able to discriminate between pa-
tients with schizophrenia and control subjects with an area under
the curve of 0.85 (Lai et al., 2011); increased miR-652 expression
was observed in these patients.
miR-15b is a member of a family of miRNAs that are implicated
in a wide range of functions and diseases including metabolism,
angiogenesis, stress response, cancer, cardiovascular disease and
neurodegenerative conditions, including Alzheimer's disease
(Finnerty et al., 2010). Decreased miR-15b expression forms part of
a seven miRNA plasma expression signature that was found to
distinguish patients with Alzheimer's disease from controls with
greater than 95% accuracy (Kumar et al., 2013). miR-132 is tran-
scribed from a cluster of miRNAs that are known to play an
important role in neuronal development and function (Wanet
et al., 2012) and decreased miR-132 expression has been
observed in Alzheimer's disease (Cogswell et al., 2008). Fewer
published studies have explored the functions of miR-652; how-
ever, it appears to play a central role in myeloid development and,
thus, innate immunity (Gilicze et al., 2014). There is evidence
linking altered innate immune function to the pathogenesis of BD
(Jones and Thomsen, 2013), suggesting one pathway by which
altered miR-652 expression might confer risk for BD. Without
sorted cell populations, we cannot determine whether this change
in expression reﬂects a change in whole blood composition;
however, should our ﬁndings be replicated, it would be important
to assess this possibility.
Table 5
Summary of the top ﬁndings from Ingenuity Pathway Analysis of the mRNA targets of miR-652.
Name p-value q-value Ratio
Canonical pathways
Biotin-carboxyl carrier protein assembly 5.20  104 6.84  102 2/4 (0.5)
Reelin signalling in neurons 8.88  104 6.84  102 5/79 (0.063)
GABA receptor signalling 3.64  103 1.87  101 4/67 (0.06)
Heparan sulfate biosynthesis (Late stages) 1.16  102 3.91  101 3/50 (0.06)
1D-myo-inositol hexakisphosphate biosynthesis II (Mammalian) 1.35  102 3.91  101 2/19 (0.105)
Name p-value range q-value range No. molecules
Molecular and cellular functions
Cell morphology 8.77  105e4.61  102 1.34  101e2.09  101 36
Cellular assembly and organization 1.43  104e4.61  102 1.34  101e2.09  101 47
Cellular function and maintenance 1.43  104e4.61  102 1.34  101e2.09  101 38
Gene expression 8.31  104e2.69  102 1.38  101e1.80  101 37
Lipid metabolism 9.95  104e4.61  102 1.38  101e2.09  101 11
Physiological system development and function
Tissue morphology 1.28  103e4.61  102 1.38  101e2.09  101 25
Skeletal and muscular system development and function 1.88  103e4.22  102 1.38  101e2.09  101 13
Behaviour 2.02  103e4.61  102 1.38  101e2.09  101 6
Haematological system development and function 3.76  103e4.61  102 1.38  101e2.09  101 11
Immune cell trafﬁcking 3.76  103e3.70  102 1.38  101e1.93  101 5
Diseases and disorders
Cancer 2.61  104e4.61  102 1.38  101e2.09  101 55
Dermatological diseases and conditions 2.61  104e2.79  102 1.38  101e1.80  101 7
Developmental disorder 2.61  104e4.61  102 1.38  101e2.09  101 18
Hereditary disorder 2.61  104e3.88  102 1.38  101e1.97  101 31
Neurological disease 2.61  104e4.61  102 1.38  101e2.09  101 39
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dysregulated miRNAs is compatible with a scenario in which a
common miRNA regulatory or processing mechanism has been
perturbed in individuals at high-risk of developing BD. Previous
studies have shown expression of components of the miRNA pro-
cessing pathway to be dysregulated in patients with schizophrenia
(Beveridge et al., 2010; Gardiner et al., 2013; Santarelli et al., 2011).
Investigating whether aspects of the miRNA processing pathway
are altered in the high-risk cohort would be of interest.
To gain an insight into the particular biological processes that
might be affected by the altered expression of miR-15b, miR-132
and miR-652 expression, we performed pathway analysis of the
experimentally observed and predicted targets of these miRNAs. Of
particular interest was the fact that the targets of miR-15b andmiR-
132 were found to be involved in PI3K/Akt signalling both directly
and, in the case of miR-15b, indirectly via the modulation of PTEN, a
negative regulator of PI3K/Akt signalling. PI3K/Akt signalling is
involved in several processes that are perturbed in psychiatric pa-
tients, including mediation of the neuroprotective effects of neu-
rotrophins, such as brain-derived neurotrophic factor (BDNF), and
the induction of long-term plasticity, which is required for learning
and memory (Zheng et al., 2012). Activation of the PI3K/Akt sig-
nalling pathway results in the inhibition of glycogen synthase
kinase-3 (GSK3). GSK3 signalling has been implicated in psychiatric
illness by multiple lines of genetic and functional evidence and the
inhibition of GSK3b is believed to be one of themainmechanisms of
action of the mood-stabilising drug lithium (Kitagishi et al., 2012).
The targets of miR-132 were found to be enriched for molecules
involved in cognitive function. Diminished cognitive ability is a
well-established phenomenon in BD (Raust et al., 2014) and has
also been observed in the ﬁrst-degree relatives of individuals with
BD (Nehra et al., 2014).
Although none of the pathway analysis results for miR-652's
targets withstood correction for multiple testing, it was of interest
to note that the top-ranked canonical pathways and diseases were
pertinent to BD. miR-652's targets were nominally signiﬁcantly
enriched for molecules implicated in BD and schizoaffective dis-
order. Amongst these targets were the gamma-aminobutyric acid(GABA) receptor subunits GABARB2 and GABARB3, the serotonin
receptor 5-HT1D, and Disrupted in Schizophrenia 1 (DISC1).
GABAergic interneuron dysfunction is believed to play a central role
in the pathogenesis of schizophrenia (Nakazawa et al., 2012) and
the interaction between DISC1 and GABA signalling has been
shown to regulate neurogenesis in mice (Kim et al., 2012). miR-
652's targets were also nominally signiﬁcantly enriched for mole-
cules involved in Reelin signalling. Reelin signalling contributes to
multiple processes relevant to the pathogenesis of schizophrenia
and BD: in development, it is involved in regulating neuronal
migration and brain lamination and in the adult brain it modulates
synaptic plasticity (Folsom and Fatemi, 2013). While there are a
small number of negative studies, the majority of gene expression
and genetic association studies implicate altered Reelin signalling
in schizophrenia and BD (Folsom and Fatemi, 2013). These ﬁndings
must, of course, be interpreted with the caveat that they failed to
attain statistical signiﬁcance after correcting for multiple testing.
This may, in part, reﬂect the fact that relatively little is known about
miR-652's function, resulting in a much shorter list of interactors
being available for pathway analysis.
Taken together, the results from our pathway analyses and the
published literature suggest several neurological systems that
might be impacted by the dysregulated expression of miR-15b,
miR-132 and miR-652, thus conferring risk for BD. Whilst the evi-
dence linking the altered expression of these miRNAs with bio-
logical pathways previously implicated in the pathogenesis of BD is
compelling, it is important to note some key limitations of the
present study. The most important limitation is the size of the
sample studied. This small sample size means that failure to
observe a change in expression in the majority of the miRNAs
measured cannot be taken as evidence that the altered expression
of these miRNAs does not represent a mechanism of genetic risk for
BD; it is possible that our study was simply underpowered to detect
small, but real, changes in expression. Moreover, it is imperative
that our ﬁnding of altered miR-15b, miR-132 and miR-652
expression is replicated in a larger independent sample.
The nature of our study design (i.e. young, unmedicated in-
dividuals at high genetic risk of BD) necessitated the measurement
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whether the changes in miRNA expression we observe in the blood
of these individuals are also present in the brain, it is of interest that
all three differentially expressed miRNAs have previously been
found to show dysregulated expression in brain tissue from pa-
tients with schizophrenia in a direction consistent with our ﬁnd-
ings (Beveridge et al., 2010; Kim et al., 2010; Santarelli et al., 2011).
We measured miRNA expression in whole-blood, which is
formed of multiple different cell types, each with its own charac-
teristic miRNA expression proﬁle. It is, therefore, possible that
apparent changes in miRNA expression might reﬂect differences in
the relative proportions of blood cell subtypes between the high-
risk and control groups. An additional issue when measuring
miRNA expression in whole-blood is the presence of cell-free
miRNAs. The snoRNAs used to normalise miRNA expression in the
current study are not likely to represent good normalisers for cell-
free miRNAs, due to the low expression of snoRNAs in this blood
component. However, compared with erythrocytes, granulocytes
and platelets, cell-free miRNAs make up a small proportion of total
miRNA expression in whole-blood RNA (Kang et al., 2012;
Sangokoya et al., 2010). Therefore, it is unlikely that the changes
in expressionwe observe are driven entirely by expression changes
in cell-free blood. Nevertheless, it would be of interest to charac-
terise the expression of miR-15b, miR-132 and miR-652 in different
blood cell types and cell-free blood. It should, however, be noted
that should a blood-based biomarker be developed to aid in the
diagnosis of schizophrenia and/or bipolar disorder, the ability to
measure this biomarker in whole-blood would vastly improve its
utility.
For all three dysregulated miRNAs there is a substantial de-
gree of overlap in expression between the control and high-risk
individuals. This likely reﬂects both the existence of varying
levels of predisposition in the high-risk group and the complex
and heterogeneous nature of BD. It is possible that those in-
dividuals who do go onto become ill, or those who become ill
and whose illness is characterised by particular features, show
the most extreme changes in miRNA expression. Longitudinal
follow-up of our sample would permit the assessment of these
possibilities. Alone, the three dysregulated miRNAs identiﬁed in
the present study would not represent a satisfactory biomarker
for BD. However, the fact that altered miRNA expression can be
detected in the blood prior to the onset of BD suggests that
further work may one day result in the identiﬁcation of blood-
based biomarkers to aid in the prediction and diagnosis of psy-
chiatric illness, as well as in the monitoring of treatment
response. Moreover, it is possible that some blood-expressed
molecules will be found to represent good biomarkers for BD
despite not being expressed in the brain.
Providing that our ﬁndings withstand replication, it would be of
great interest to characterise the expression levels of miR-15b, miR-
132 and miR-652 in members of the high-risk group who go on to
develop psychiatric illness. A key aim of future studies will be to
establishwhether we can detect differences in gene expression that
are predictive of the onset of illness, or indeed differences in gene
expression that might suggest mechanisms of resilience. Moreover,
characterisation of the downstream pathways affected by the
altered expression of these miRNAs is essential in order to build a
mechanistic understanding of the biological underpinnings of ge-
netic risk for BD.
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